Captrust Financial Advisors Buys Shares of 4,133 LivaNova PLC (NASDAQ:LIVN)

Captrust Financial Advisors bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,133 shares of the company’s stock, valued at approximately $217,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Arizona State Retirement System boosted its position in LivaNova by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock valued at $828,000 after acquiring an additional 299 shares in the last quarter. Atria Investments Inc boosted its position in shares of LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares in the last quarter. State of Alaska Department of Revenue boosted its position in shares of LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of LivaNova by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock worth $10,039,000 after purchasing an additional 659 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on LIVN shares. Mizuho lowered their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. The Goldman Sachs Group began coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research note on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $69.17.

LivaNova Trading Down 1.2 %

LIVN stock opened at $51.50 on Monday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 12-month low of $43.15 and a 12-month high of $64.47. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 122.62 and a beta of 0.98. The business’s 50-day moving average is $51.97 and its 200 day moving average is $51.43.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.